Compare EFOI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | PULM |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 14.9M |
| IPO Year | 1994 | N/A |
| Metric | EFOI | PULM |
|---|---|---|
| Price | $2.19 | $4.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.6K | 9.5K |
| Earning Date | 11-12-2025 | 10-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,863,000.00 | $3,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $134.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $3.90 |
| 52 Week High | $3.56 | $10.40 |
| Indicator | EFOI | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 49.50 |
| Support Level | $1.93 | $3.95 |
| Resistance Level | $2.83 | $4.48 |
| Average True Range (ATR) | 0.24 | 0.32 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 29.67 | 50.96 |
Energy Focus Inc engages in the design, development, manufacturing, marketing, and sale of energy-efficient lighting systems and controls. The company serves the military maritime market and general commercial markets. Its product offerings include Military maritime LED lighting products such as military intelligible, globe lights, berth lights, and military fixtures and Commercial products such as LED fixtures and panels, LED down-lights, LED dock lights, and LED retrofit kits. Geographically, it operates in the United States and other countries. Its products include commercial products and MMM products. The company generates a majority of its sales from Military maritime products in the United States.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).